Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1992 1
1993 1
1994 3
1995 1
1996 1
1997 1
1999 3
2000 6
2001 7
2002 10
2003 6
2004 5
2005 4
2006 6
2007 7
2008 6
2009 10
2010 9
2011 8
2012 8
2013 6
2014 11
2015 12
2016 9
2017 15
2018 10
2019 20
2020 24
2021 23
2022 29
2023 19
2024 25
2025 28
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Results by year

Filters applied: . Clear all
Page 1
The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics.
Naesens M, Roufosse C, Haas M, Lefaucheur C, Mannon RB, Adam BA, Aubert O, Böhmig GA, Callemeyn J, Clahsen-van Groningen M, Cornell LD, Demetris AJ, Drachenberg CB, Einecke G, Fogo AB, Gibson IW, Halloran P, Hidalgo LG, Horsfield C, Huang E, Kikić Ž, Kozakowski N, Nankivell B, Rabant M, Randhawa P, Riella LV, Sapir-Pichhadze R, Schinstock C, Solez K, Tambur AR, Thaunat O, Wiebe C, Zielinski D, Colvin R, Loupy A, Mengel M. Naesens M, et al. Among authors: bohmig ga. Am J Transplant. 2024 Mar;24(3):338-349. doi: 10.1016/j.ajt.2023.10.016. Epub 2023 Oct 28. Am J Transplant. 2024. PMID: 38032300 Free article.
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.
Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S, Haindl S, Kasbohm S, Kainz A, Eskandary F, Doberer K, Patel UD, Dudani JS, Regele H, Kozakowski N, Kläger J, Boxhammer R, Amann K, Puchhammer-Stöckl E, Vietzen H, Beck J, Schütz E, Akifova A, Firbas C, Gilbert HN, Osmanodja B, Halleck F, Jilma B, Budde K, Böhmig GA. Mayer KA, et al. Among authors: bohmig ga. N Engl J Med. 2024 Jul 11;391(2):122-132. doi: 10.1056/NEJMoa2400763. Epub 2024 May 25. N Engl J Med. 2024. PMID: 38804514 Clinical Trial.
Antibody-mediated rejection-treatment standard.
Böhmig GA, Naesens M, Viklicky O, Thaunat O, Diebold M, Rostaing L, Budde K. Böhmig GA, et al. Nephrol Dial Transplant. 2025 Aug 1;40(8):1615-1627. doi: 10.1093/ndt/gfaf097. Nephrol Dial Transplant. 2025. PMID: 40440205 Free PMC article. Review.
Chronic Rejection After Kidney Transplantation.
Diebold M, Mayer KA, Hidalgo L, Kozakowski N, Budde K, Böhmig GA. Diebold M, et al. Among authors: bohmig ga. Transplantation. 2025 Apr 1;109(4):610-621. doi: 10.1097/TP.0000000000005187. Epub 2024 Aug 28. Transplantation. 2025. PMID: 39192468 Free PMC article. Review.
Targeting CD38 in Antibody-Mediated Rejection.
Mayer KA, Budde K, Diebold M, Halloran PF, Böhmig GA. Mayer KA, et al. Among authors: bohmig ga. Transpl Int. 2025 May 15;38:14343. doi: 10.3389/ti.2025.14343. eCollection 2025. Transpl Int. 2025. PMID: 40444214 Free PMC article. Review.
A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, Reeve J, Borski A, Kozakowski N, Reindl-Schwaighofer R, Waiser J, Lachmann N, Schranz S, Firbas C, Mühlbacher J, Gelbenegger G, Perkmann T, Wahrmann M, Kainz A, Ristl R, Halleck F, Bond G, Chong E, Jilma B, Böhmig GA. Doberer K, et al. Among authors: bond g, wahrmann m, bohmig ga. J Am Soc Nephrol. 2021 Mar;32(3):708-722. doi: 10.1681/ASN.2020071106. Epub 2020 Dec 18. J Am Soc Nephrol. 2021. PMID: 33443079 Free PMC article. Clinical Trial.
CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection.
Doberer K, Kläger J, Gualdoni GA, Mayer KA, Eskandary F, Farkash EA, Agis H, Reiter T, Reindl-Schwaighofer R, Wahrmann M, Cohen G, Haslacher H, Bond G, Simonitsch-Klupp I, Halloran PF, Böhmig GA. Doberer K, et al. Among authors: bond g, wahrmann m, bohmig ga. Transplantation. 2021 Feb 1;105(2):451-457. doi: 10.1097/TP.0000000000003247. Transplantation. 2021. PMID: 32235256
Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study.
Loupy A, Aubert O, Orandi BJ, Naesens M, Bouatou Y, Raynaud M, Divard G, Jackson AM, Viglietti D, Giral M, Kamar N, Thaunat O, Morelon E, Delahousse M, Kuypers D, Hertig A, Rondeau E, Bailly E, Eskandary F, Böhmig G, Gupta G, Glotz D, Legendre C, Montgomery RA, Stegall MD, Empana JP, Jouven X, Segev DL, Lefaucheur C. Loupy A, et al. Among authors: bohmig g. BMJ. 2019 Sep 17;366:l4923. doi: 10.1136/bmj.l4923. BMJ. 2019. PMID: 31530561 Free PMC article. Clinical Trial.
Functional Natural Killer-cell Genetics and Microvascular Inflammation After Kidney Transplantation: An Observational Cohort Study.
Diebold M, Vietzen H, Schatzl M, Mayer KA, Haindl S, Heinzel A, Hittmeyer P, Herz CT, Hopfer H, Menter T, Kühner LM, Berger SM, Puchhammer-Stöckl E, Doberer K, Steiger J, Schaub S, Böhmig GA. Diebold M, et al. Among authors: bohmig ga. Transplantation. 2025 May 1;109(5):860-870. doi: 10.1097/TP.0000000000005228. Epub 2025 Apr 17. Transplantation. 2025. PMID: 39402708 Free PMC article.
294 results